New drug targets for HIV

Clinical Infectious Diseases

Volumn 41, Issue 1 SUPPL., 2005, Pages

  Bean, Pamela ^a  

^a ROGERS MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 3' FLUOROTHYMIDINE; 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ALUVIRAN; AMDOXOVIR; AMPRENAVIR; ANALGESIC AGENT; ANTIRETROVIRUS AGENT; APLAVIROC; ATAZANAVIR; AXD 455; AZOFORMAMIDE; CALANOLIDE A; CAPRAVIRINE; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CREATININE; CYANOVIRIN N; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ELVUCITABINE; EMTRICITABINE; ENFUVIRTIDE; GAG PROTEIN; GPG NH2; GSK 873140; INDINAVIR; INTEGRASE INHIBITOR; L 870812; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MEDIVIR; NELFINAVIR; NEVIRAPINE; PRO 2000; PROTEIN GP41; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; REVETAZ; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; T 1249; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; TNX 355; UNCLASSIFIED DRUG; VICRIVIROC; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; ZALCITABINE; ZIDOVUDINE; ZINC FINGER PROTEIN;

BLOOD BRAIN BARRIER; CELL FUSION; CELL MEMBRANE; CREATININE BLOOD LEVEL; DRUG ACTIVITY; DRUG PENETRATION; ECCHYMOSIS; ENZYME INHIBITION; ERYTHEMA; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; KIDNEY COLIC; NEPHROLITHIASIS; NEPHROTOXICITY; PAIN; PRIORITY JOURNAL; PRURITUS; QT INTERVAL; REVIEW; SIDE EFFECT; SKIN CYST; SKIN INDURATION; SKIN NODULE; TREATMENT FAILURE; VIRUS ADSORPTION; VIRUS ENVELOPE; VIRUS REPLICATION;

ANIMALS; ANTI-RETROVIRAL AGENTS; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS;

EID: 20844460158     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429504     Document Type: Review

References (23)

1. Brenner BG, Turner D, Wainberg MA. HIV-1 drug resistance: can we overcome? Expert Opin Biol Ther 2002; 2:751-61.
2. Morris A, Watcher RM, Luce J, et al. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003; 17:73-80.
3. Stolk LM, Luers JF. Increasing number of anti-HIV drugs but no definite cure: review of anti-HIV drugs. Pharm World Sci 2004; 26:133-6.
4. Markovic I, Clouse KA. Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. Curr HIV Res 2004; 2:223-34.
5. Pierson TC, Doms RW, Pohlmann S. Prospects of HIV-1 entry inhibitors as novel therapeutics. Rev Med Virol 2004; 14:255-70.
6. Vermeire K, Schols D, Bell TW. CD4 down-modulating compounds with potent anti-HIV activity. Curr Pharm Des 2004; 10:1795-803.
7. Seibert C, Sakmar TP. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs. Curr Pharm Des 2004; 10: 2041-62.
8. Bean P. A brief update on chemokines, chemokine receptors, and HIV. Am Clin Lab 2002; 21:14-6.
9. Schols D. HIV co-receptors as targets for antiviral therapy. Curr Top Med Chem 2004; 4:883-93.
10. Este JA. Sch-351125 and Sch-350634. Schering-Plough. Curr Opin Investig Drugs 2002; 3:379-83.
11. Maeda K, Nakata H, Koh Y, et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 2004; 78:8654-62.
12. Marks K, Gulick RM. New antiretroviral agents for the treatment of HIV infection. Curr Infect Dis Rep 2004; 6:333-9.
13. Clapham PR, McKnight A. Cell surface receptors, virus entry, and tropism of primate lentiviruses. J Gen Virol 2002; 83:1809-29.
14. Jamjian MC, McNicholl IR. Enfuvirtide: first fusion inhibitor for treatment of HIV infection. Am J Health Syst Pharm 2004; 61:1242-7.
15. Ball RA, Kinchelow T. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. ISR Substudy Group. J Am Acad Dermatol 2003; 49:826-31.
16. Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004; 54:333-40.
17. Sista PR, Melby T, Davison D, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004; 18:1787-94.
18. Bean P. HIV genetic mutations causing resistance to the new drug T-20: recent findings. Am Clin Lab 2002; 21:15-6.
19. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004; 305:528-32.
20. Dayam R, Neamati N. Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update. Curr Pharm Des 2003; 9:1789-802.
21. Johnson AA, Marchand C, Pommier Y. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Curr Top Med Chem 2004; 4:1059-77.
22. Druillennec S, Roques BP. HIV-1 NCp7 as a target for the design of novel antiviral agents. Drug News Perspect 2000; 13:337-49.
23. Goebel FD, Hemmer R, Schmit JC, et al. Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy. AIDS 2001; 15:33-45.